Abivax (AAVXF) Depreciation & Amortization (CF) (2024 - 2026)

Abivax has reported Depreciation & Amortization (CF) for 3 years, with the latest figure at $429663.7 in Q1 2026.

• On a quarterly basis, Depreciation & Amortization (CF) rose 49.62% year-over-year to $429663.7 in Q1 2026; TTM through Mar 2026 was $1.2 billion, a 6.16% increase from a year earlier, with the FY2025 full-year figure at $1.2 billion, up 6.16% from the prior year.
• Depreciation & Amortization (CF) was $429663.7 for Q1 2026 at Abivax, down from $1.2 billion in the prior quarter.
• The five-year high for Depreciation & Amortization (CF) was $1.2 billion in Q4 2025, with the low at $229222.3 in Q1 2024.
• Average Depreciation & Amortization (CF) over 3 years is $269.3 million, with a median of $317983.0 recorded in 2025.
• The sharpest annual moves came in 2025 and 2026: Depreciation & Amortization (CF) declined 27.72% in 2025, then surged 49.62% in 2026.
• Over 3 years, Depreciation & Amortization (CF) stood at $1.2 billion in 2024, then increased by 6.16% to $1.2 billion in 2025, then tumbled by 99.97% to $429663.7 in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $429663.7 (Q1 2026), $1.2 billion (Q4 2025), and $317983.0 (Q3 2025), per Business Quant data.